Archive · 23 Jan 2026
Novo Medi Sciences Launches NEXIPOX PLUS® Varicella Vaccine
Novo Medi Sciences, a company with 80 years of experience, has launched a new chickenpox vaccine called NEXIPOX PLUS®.
This vaccine is special because it uses a unique formula that makes it more stable and effective, especially in the real-world conditions of India.
It has been tested and shown to be very safe and effective, with a high success rate in creating immunity.
The company hopes this vaccine will help reduce the number of chickenpox cases in India and make it easier for people to get vaccinated.
The vaccine is approved for use in children from 12 months old and has patent protection in many countries.
Novo Medi Sciences launched NEXIPOX PLUS®, a next-generation varicella vaccine designed for Indian patients and healthcare settings.
The vaccine features a 2X trehalose-based stabiliser system, enhancing viral stability and reducing allergic reactions.
Clinical trials showed a 98% seroconversion rate and a 35.4-fold rise in antibody titres, indicating strong immune response.
NEXIPOX PLUS® has a favourable safety profile with no serious adverse events linked to the vaccine.
The vaccine is approved by the DCGI for use from 12 months of age and is patented in 156 countries.
- Who
- Novo Medi Sciences Pvt. Ltd. (Novo Group)
- What
- Launched NEXIPOX PLUS®, a next-generation varicella vaccine
- When
- January 23 (announcement date)
- Where
- Mumbai, India
- Why
- To address the unique clinical, environmental, and operational needs of Indian patients and healthcare settings
- Company
- Novo Medi Sciences Pvt. Ltd. (Novo Group)
- Vaccine Name
- NEXIPOX PLUS®
- Key Feature
- 2X trehalose-based stabiliser system
- Seroconversion Rate
- 98% following a two-dose schedule
- Antibody Titre Rise
- 35.4-fold geometric mean rise
- Approval
- Drugs Controller General of India (DCGI)
- Age for Use
- 12 months and above
- Patent Coverage
- 156 countries